Laboratory of Pharmacology, College of Pharmacy, Department of Life Nanopharmaceutical Sciences, Graduate School, Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Republic of Korea.
Prog Lipid Res. 2020 Apr;78:101034. doi: 10.1016/j.plipres.2020.101034. Epub 2020 Apr 30.
Maresin-1, a pro-resolving lipid mediator, is drawing a great deal of attention in receptor pharmacology, largely because two distinct types of receptor molecules have been reported as the targets of maresin-1. One is retinoic acid-related orphan receptor α (RORα) and the other is leucine-rich repeat domain-containing G protein-coupled receptor 6 (LGR6). RORα is a nuclear receptor and LGR6 is a plasma membrane GPCR. Identification of two different molecular targets raises the following question: What are the pro-resolving functions of each receptor in inflammation resolution, host defense, tissue homeostasis, and wound healing? In this article, I review the new targets from the point of view of pharmacology and maresin-1 resolution along with intracellular signaling molecules.
maresin-1,一种促解决的脂质介质,在受体药理学中引起了极大的关注,主要是因为已经报道了两种不同类型的受体分子作为maresin-1 的靶标。一种是维甲酸相关孤儿受体α(RORα),另一种是富含亮氨酸重复域的 G 蛋白偶联受体 6(LGR6)。RORα 是一种核受体,LGR6 是一种质膜 GPCR。两种不同分子靶标的鉴定提出了以下问题:每个受体在炎症消退、宿主防御、组织动态平衡和伤口愈合中的促解决功能是什么?在本文中,我从药理学和maresin-1 分辨率的角度以及细胞内信号分子的角度来回顾新的靶标。